These data define Glioblastoma subsets that might be sensitive (Dll4+/Jagged1+) or resistant (Dll4+/Jagged1-) to bevacizumab, a humanized monoclonal antibody against VEGF [143]. This evidence concerns the gene JAG1 and glioblastoma.